28275119|t|Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
28275119|a|Despite involvement of PI3K pathway activation in tumorigenesis of solid tumors, single-agent PI3K inhibitors have shown modest clinical activity. Preclinical evidence suggests that combining PI3K pathway inhibitors and chemotherapy can enhance antitumor effects .In patients with solid tumors, the PI3K inhibitor pilaralisib had a favorable safety profile but did not enhance the antitumor activity of paclitaxel plus carboplatin .Further clinical evaluation is warranted to identify effective combination strategies with PI3K pathway inhibitors. Pilaralisib (SAR245408) is an oral, pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. This phase I dose-escalation study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics of pilaralisib in capsule and tablet formulations, administered in combination with paclitaxel and carboplatin in patients with advanced solid tumors. A 3 + 3 design was used. Pilaralisib was administered once daily (QD); paclitaxel (up to 175 mg/m(2)) and carboplatin (up to area under the curve [AUC] of 6) were administered on day 1 of 21-day cycles. An MTD expansion cohort of patients with endometrial carcinoma was included. Fifty-eight patients were enrolled. Six patients (10.3%) had dose-limiting toxicities, of which only rash (two patients, 3.4%) occurred in more than one patient. The MTD of pilaralisib tablets in combination with paclitaxel and carboplatin was determined to be 200 mg QD. The most frequently reported adverse events (AEs) of any grade were neutropenia (67.2%) and thrombocytopenia (67.2%). PK data showed no interaction between pilaralisib and paclitaxel/carboplatin. Tumor tissue showed moderate inhibition of PI3K and mitogen-activated protein kinase (MAPK) pathways. Seven of 52 evaluable patients had a partial response (PR; 13.5%). Pilaralisib had a favorable safety profile but did not enhance the antitumor activity of paclitaxel plus carboplatin in solid tumors. The Oncologist 2017;22:377-378.
28275119	0	7	Phase I	T062	C0920321
28275119	8	23	Dose-Escalation	T169	C3816728
28275119	24	29	Study	T062	C2603343
28275119	33	44	Pilaralisib	T121	C1254351
28275119	46	55	SAR245408	T109,T121	C3657458
28275119	57	62	XL147	T109,T121	C2347424
28275119	67	110	Combination with Paclitaxel and Carboplatin	T061	C0281297
28275119	114	122	Patients	T101	C0030705
28275119	128	140	Solid Tumors	T191	C0280100
28275119	164	176	PI3K pathway	T169	C2984368
28275119	177	187	activation	T052	C1879547
28275119	191	204	tumorigenesis	T191	C0007621
28275119	208	220	solid tumors	T191	C0280100
28275119	235	250	PI3K inhibitors	T116,T126	C4041090
28275119	269	286	clinical activity	T185	C1516654
28275119	288	299	Preclinical	T080	C1709630
28275119	300	308	evidence	T078	C3887511
28275119	323	332	combining	T080	C0205195
28275119	333	356	PI3K pathway inhibitors	T116,T126	C4041090
28275119	361	373	chemotherapy	T061	C3665472
28275119	378	385	enhance	T052	C2349975
28275119	386	403	antitumor effects	T033	C0243095
28275119	408	416	patients	T101	C0030705
28275119	422	434	solid tumors	T191	C0280100
28275119	440	454	PI3K inhibitor	T116,T126	C4041090
28275119	455	466	pilaralisib	T121	C1254351
28275119	483	489	safety	T062	C1705187
28275119	490	497	profile	T059	C1979963
28275119	510	517	enhance	T052	C2349975
28275119	522	540	antitumor activity	T033	C0243095
28275119	544	571	paclitaxel plus carboplatin	T061	C0281297
28275119	581	600	clinical evaluation	T058	C4084924
28275119	626	635	effective	T080	C1704419
28275119	636	647	combination	T121	C0013162
28275119	664	687	PI3K pathway inhibitors	T116,T126	C4041090
28275119	689	700	Pilaralisib	T121	C1254351
28275119	702	711	SAR245408	T109,T121	C3657458
28275119	719	723	oral	T122	C1272919
28275119	725	736	pan-class I	T185	C0441885
28275119	737	779	phosphoinositide 3-kinase (PI3K) inhibitor	T116,T126	C4041090
28275119	786	793	phase I	T062	C0920321
28275119	794	809	dose-escalation	T169	C3816728
28275119	810	815	study	T062	C2603343
28275119	816	825	evaluated	T058	C0220825
28275119	830	852	maximum tolerated dose	T081	C0752079
28275119	854	857	MTD	T081	C0752079
28275119	860	866	safety	T062	C1705187
28275119	868	884	pharmacokinetics	T039	C0031327
28275119	886	888	PK	T039	C0031327
28275119	895	911	pharmacodynamics	T038	C0851347
28275119	915	926	pilaralisib	T121	C1254351
28275119	930	937	capsule	T122	C0006935
28275119	942	948	tablet	T122	C0039225
28275119	949	961	formulations	T122	C0013058
28275119	963	975	administered	T169	C1521801
28275119	979	1022	combination with paclitaxel and carboplatin	T061	C0281297
28275119	1026	1034	patients	T101	C0030705
28275119	1040	1048	advanced	T080	C0205179
28275119	1049	1061	solid tumors	T191	C0280100
28275119	1071	1077	design	T052	C1707689
28275119	1088	1099	Pilaralisib	T121	C1254351
28275119	1104	1116	administered	T169	C1521801
28275119	1117	1127	once daily	T079	C0556983
28275119	1129	1131	QD	T079	C0556983
28275119	1134	1144	paclitaxel	T109,T121	C0144576
28275119	1169	1180	carboplatin	T109,T121	C0079083
28275119	1188	1208	area under the curve	T081	C0376690
28275119	1210	1213	AUC	T081	C0376690
28275119	1226	1238	administered	T169	C1521801
28275119	1258	1264	cycles	T079	C1511572
28275119	1269	1272	MTD	T081	C0752079
28275119	1283	1289	cohort	T098	C0599755
28275119	1293	1301	patients	T101	C0030705
28275119	1307	1328	endometrial carcinoma	T191	C0476089
28275119	1333	1341	included	T169	C0332257
28275119	1355	1363	patients	T101	C0030705
28275119	1383	1391	patients	T101	C0030705
28275119	1404	1417	dose-limiting	T078	C1512043
28275119	1418	1428	toxicities	T037	C0013221
28275119	1444	1448	rash	T184	C0015230
28275119	1454	1462	patients	T101	C0030705
28275119	1470	1478	occurred	T052	C1709305
28275119	1496	1503	patient	T101	C0030705
28275119	1509	1512	MTD	T081	C0752079
28275119	1516	1527	pilaralisib	T121	C1254351
28275119	1528	1535	tablets	T122	C0039225
28275119	1539	1582	combination with paclitaxel and carboplatin	T061	C0281297
28275119	1611	1613	QD	T079	C0556983
28275119	1624	1634	frequently	T079	C0332183
28275119	1635	1643	reported	T058	C0700287
28275119	1644	1658	adverse events	T046	C0877248
28275119	1660	1663	AEs	T046	C0877248
28275119	1672	1677	grade	T185	C0441800
28275119	1683	1694	neutropenia	T047	C0027947
28275119	1707	1723	thrombocytopenia	T047	C0040034
28275119	1733	1735	PK	T039	C0031327
28275119	1736	1740	data	T078	C1511726
28275119	1748	1750	no	T033	C1513916
28275119	1751	1762	interaction	T044	C0687133
28275119	1771	1782	pilaralisib	T121	C1254351
28275119	1787	1809	paclitaxel/carboplatin	T061	C0281297
28275119	1811	1823	Tumor tissue	T024	C0475358
28275119	1831	1839	moderate	T080	C1881878
28275119	1840	1850	inhibition	T044	C0021469
28275119	1854	1858	PI3K	T169	C2984368
28275119	1863	1911	mitogen-activated protein kinase (MAPK) pathways	T043	C1518102
28275119	1925	1943	evaluable patients	T101	C2986511
28275119	1950	1966	partial response	T033	C1521726
28275119	1968	1970	PR	T033	C1521726
28275119	1980	1991	Pilaralisib	T121	C1254351
28275119	1998	2007	favorable	T080	C3640814
28275119	2008	2014	safety	T062	C1705187
28275119	2015	2022	profile	T059	C1979963
28275119	2035	2042	enhance	T052	C2349975
28275119	2047	2065	antitumor activity	T033	C0243095
28275119	2069	2096	paclitaxel plus carboplatin	T061	C0281297
28275119	2100	2112	solid tumors	T191	C0280100